US Supreme Court Temporarily Restores Telehealth Access to Abortion Pill Mifepristone
The United States Supreme Court has temporarily restored telehealth and mail access to the abortion pill mifepristone, responding to an emergency appeal that warned of potential chaos and upheaval for patients who had appointments to access the widely used drug.
The United States Supreme Court has temporarily restored telehealth and mail access to the abortion pill mifepristone, responding to an emergency appeal that warned of potential chaos and upheaval for patients who had appointments to access the widely used drug. The administrative stay, issued by Justice Samuel Alito, is far from a final decision but maintains the status quo for a few days while the court reviews emergency appeals filed by the drug's manufacturer Danco Laboratories and GenBioPro, the maker of a generic version.
The order puts on hold a ruling from the conservative 5th US Circuit Court of Appeals that had reinstated a nationwide requirement that mifepristone be obtained in person, severely undermining access to the most common method of abortion in the United States. Alito's order staying the 5th Circuit ruling lasts through May 11, with a response in the cases requested by Thursday. Fight over Pills Pits Abortion Opponents Against Trump Administration.
Danco Laboratories told the Supreme Court in its appeal that the 5th Circuit order injects immediate confusion and upheaval into highly time-sensitive medical decisions, while GenBioPro warned that the lower court's decision risked abruptly cutting off access for patients nationwide. Since the Covid-19 pandemic, women have been able to obtain mifepristone through telehealth appointments, following the Biden administration's 2023 rules that ended the requirement for an in-person doctor's visit. US FDA Allows Sale of Abortion Pills at Retail Pharmacies: Reports.
As conservative states have responded to the Supreme Court's overturning of Roe v. Wade by banning or severely limiting access to clinic abortions, medication abortions have grown significantly more common, accounting for more than 60% of all abortions in the United States in 2023, according to Guttmacher Institute research.
The fast-track case puts mifepristone and the broader issue of abortion access back on the Supreme Court's docket less than two years after the justices unanimously rejected a similar challenge in 2024, allowing the drug to remain widely available. That earlier decision was resolved on narrow technical grounds of legal standing, making future challenges almost inevitable.
A CNN analysis of mifepristone data shows that the drug is overwhelmingly safe, with fewer reported side effects than common medications such as Viagra or penicillin. Louisiana had sued last year alleging that Biden-era regulations undermined its own state abortion ban, setting off the latest legal battle now before the nation's highest court.
(The above story first appeared on LatestLY on May 04, 2026 09:00 PM IST. For more news and updates on politics, world, sports, entertainment and lifestyle, log on to our website latestly.com).